Brief: Canbridge Pharmaceuticals Says HY Revenue Increased 24.2% To RMB43.1 Million
31/08/2023 02:27
Aug 31 (Reuters) - Canbridge Pharmaceuticals Inc
1228.HK :
* HY REVENUE INCREASED 24.2% TO RMB43.1 MILLION
* HY LOSS RMB218.2 MILLION VERSUS LOSS RMB249.0 MILLION
Source text for Eikon: ID:nHKS6CgKMg
Further company coverage: 1228.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares